DUBLIN--(BUSINESS WIRE)--Jan 5, 2021--

The "Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials and Trends, 2021" report has been added to ResearchAndMarkets.com's offering.

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of our immune system and play a key role in directing the immune response and killing cells infected by pathogens. In CAR-T cell therapy, blood is drawn from the patient and the T-cells are separated out. In the laboratory, a disarmed virus is then used to genetically engineer the T-cells to produce chimeric antigen receptors (CARs) on their surface. These receptors are synthetic and do not exist naturally. Once infused into the patient, these CARs enable the T-cells to recognize and get attached to an antigen (specific protein) on the tumor cell leading to the destruction of the tumor.

Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, an exponential increase in clinical trial activity, proliferative M&A activity, and lucrative IPOs have created a robust CAR-T cell market. This billion dollar market would not have been possible without the remarkable efficacy of Kymriah, Yescarta, and Tecartus in treating several types of blood cancers.

Today, the CAR-T cell therapy industry is witnessing:

  • Landmark approvals of CAR-T cell therapies by regulatory bodies worldwide
  • Lucrative acquisitions within the CAR-T industry
  • Large IPOs within the industry
  • An increasingly competitive IP environment
  • Unprecedented investment flowing into CAR-T cell research

This global strategic report reveals:

  • Market size determinations with segmentation and forecasts through 2027
  • Approved CAR-T products by indication and region
  • Clinical trial activity by type, region, phase, and sponsor
  • CAR-T industry M&A transactions and IPOs
  • Strategic partnerships and commercialization agreements
  • Industry trends and future directions
  • Competitors composing the global marketplace

This 232-page global strategic report will position you to:

  • Capitalize on emerging trends
  • Improve internal decision-making
  • Reduce company risk
  • Approach outside partners and investors
  • Out compete your competition
  • Implement an informed and advantageous business strategy in 2021

Key Topics Covered:

1. Report Overview

2. Chimeric Antigen Receptor-T (Car-T) Cell Therapy: A Brief Overview

3. History of CAR-T Cell Therapy

4. Manufacture of CAR-T Cells

5. CAR-T Target Antigens: A Brief Overview

6. CAR-T Patent Landscape

7. Global CAR-T Clinical Trials: An Overview

8. Published Scientific Papers & NIH Grants

9. Deals in CAR-T Therapy Space

9.1 Most Recent CAR-T Deals

9.1.1 Gilead Sciences/Tango Therapeutics

9.1.2 Kite/Teneobio

9.1.3 Fate/Janssen

9.1.4 Juno/Oxford Biomedica

9.1.5 Allogene/MaxCyte

9.1.6 Applied DNA Sciences, Inc.

9.1.7 Cellectis/Servier

9.1.8 Cell Therapies, Pvt. Ltd

9.1.9 Astellas/Adaptimmune

9.1.10 Astellas/Xyphos

9.1.11 Carisma Therapeutics, Inc./NYU Langone Health

10. Marketed CAR-T Products

11. Reimbursement for Car-T Therapies

12. Blood Cancers: An Overview

13. Market Analysis

13.1 Global Market for CAR-T Cell Therapy by Product

13.2 Global CAR-T Market by Geography

13.3 Global Market for CAR-T Therapy by Indication

13.4 Companies at the Forefront of CAR-T Market

13.5 Barriers and Strategies for Success in CAR-T 2.0 Market Place

14. Company Profiles

14.1 Aleta BioTherapeutics

14.2 Allogene Therapeutics

14.3 Anixa Biosciences, Inc.

14.4 Attars Biotherapeutics

14.5 Autolus Therapeutics, plc

14.6 Bellicum Pharmaceuticals, Inc.

14.7 BioNTech

14.8 bluebird bio

14.9 Carina Biotech

14.10 CARsgen Therapeutics

14.11 Cartesian Therapeutics, Inc.

14.12 CARTherics

14.13 Celgene Corporation

14.14 Cellectis

14.15 Celularity, Inc.

14.16 Celyad Oncology

14.17 Creative Biolabs

14.18 CRISPR Therapeutics

14.19 Cytovia Therapeutics

14.20 DiaCarta, Inc.

14.21 Empirica Therapeutics

14.22 Eureka Therapeutics, Inc.

14.23 EXUMA Biotech Corp.

14.24 Fate Therapeutics, Inc.

14.25 Formula Pharmaceuticals, Inc.

14.26 Gilead Sciences, Inc.

14.27 Gracell Biotechnologies

14.28 iCell Gene Therapeutics

14.29 Janssen Biotech, Inc.

14.30 Juno Therapeutics

14.31 JW Therapeutics, Co., Ltd.

14.32 Kite Pharma, Inc.

14.33 MaxCyte, Inc.

14.34 Minerva Biotechnologies Corporation

4.35 Mustang Bio, Inc.

14.36 Nanjing Legend Biotechnology Co., Ltd.

14.37 Noile-Immune Biotech

14.38 Novartis International, AG

14.39 Oxford Biomedica plc

14.40 PeproMene Bio, Inc.

14.41 Poseida Therapeutics, Inc.

14.42 Precigen, Inc.

14.43 Precision Biosciences

14.44 Prescient Therapeutics

14.45 ProMab Biotechnologies, Inc.

14.46 Protheragen

14.47 Sorrento Therapeutics, Inc.

14.48 TC Biopharm

14.49 T-CURX

14.50 Tessa Therapeutics, Pvt. Ltd.

14.51 Tmunity Therapeutics, Inc.

14.52 Wugen

14.53 Xyphos Biosciences, Inc.

14.54 Ziopharm Oncology, Inc.

For more information about this report visit www.researchandmarkets.com/r/byjfeg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

View source version on businesswire.com:www.businesswire.com/news/home/20210105005755/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 01/05/2021 11:46 AM/DISC: 01/05/2021 11:46 AM


Source link